INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer

被引：5

作者：

Jessen, Katayoun A. ^{[1
]}

Kessler, Linda ^{[1
]}

Kucharski, Jeff ^{[1
]}

Guo, Xin ^{[1
]}

Staunton, Jocelyn ^{[1
]}

Elia, Marikka ^{[1
]}

Janes, Matthew ^{[1
]}

Lan, Lucy ^{[1
]}

Wang, Shunyou ^{[1
]}

Stewart, Josh ^{[1
]}

Darjania, Levan ^{[1
]}

Li, Liansheng ^{[1
]}

Chan, Katrina ^{[1
]}

Martin, Michael ^{[1
]}

Ren, Pingda ^{[1
]}

Fruman, David ^{[2
]}

Rommel, Christian ^{[1
]}

Liu, Yi ^{[1
]}

机构：

[1] Intellikine, La Jolla, CA USA

[2] UC Irvine, Irvine, CA USA

来源：

CANCER RESEARCH | 2011年 / 71卷

关键词：

D O I：

10.1158/1538-7445.AM2011-4501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4501

引用

页数：1

共 50 条

[41] Discovery of fluoroquinolone derivatives as potent, selective inhibitors of PI3Kγ
Sha, Shao
Han, Hong-Wei
Gao, Fei
Liu, Tian-Bao
Li, Zhen
Xu, Chi
Zhong, Wei-Qing
Zhu, Hai-Liang
[J]. MEDCHEMCOMM, 2015, 6 (11) : 2029 - 2035
[42] VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Hart, Stefan
Novotny-Diermayr, Veronica
Goh, Kee Chuan
Williams, Meredith
Tan, Yong Cheng
Ong, Lai Chun
Cheong, Albert
Ng, Bee Kheng
Amalini, Chithra
Madan, Babita
Nagaraj, Harish
Jayaraman, Ramesh
Pasha, Khalid M.
Ethirajulu, Kantharaj
Chng, Wee Joo
Mustafa, Nurulhuda
Goh, Boon Cher
Benes, Cyril
McDermott, Ultan
Garnett, Mathew
Dymock, Brian
Wood, Jeanette M.
[J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) : 151 - 161
[43] Synthesis and SAR study of potent and selective PI3Kδ inhibitors
Bui, Minna
Hao, Xiaolin
Shin, Youngsook
Cardozo, Mario
He, Xiao
Henne, Kirk
Suchomel, Julia
McCarter, John
Mcgee, Lawrence R.
Miguel, Tisha San
Medina, Julio C.
Mohn, Deanna
Tran, Thuy
Wannberg, Sharon
Wong, Jamie
Wong, Simon
Zalameda, Leeanne
Metz, Daniela
Cushing, Timothy D.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (05) : 1104 - 1109
[44] Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis
Yu, Mengyao
Wang, Xian
Tang, Yongmei
Wang, Longling
Hu, Xueping
Weng, Qinjie
Wang, Jiajia
Cui, Sunliang
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (11) : 9628 - 9644
[45] Precision medicine: Novel PI3K inhibitor as cancer treatment.
Hutchings, Kasen Reed
Beck, Patrick
Qiu, Rebecca
Bui, Vincent
Sheng, Zhi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[46] BAY 1082439, a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN
Liu, Ningshu
Scott, William J.
Haegebarth, Andrea
Moenning, Ursula
Fricke, Robert
Boemer, Ulf
Bruening, Michael
Mumberg, Dominik
Brands, Michael
Ziegelbauer, Karl
[J]. CANCER RESEARCH, 2012, 72
[47] Orally efficacious, selective FLT3 inhibitor for the treatment of acute myeloid leukemia
Kreutter, Kevin
Baindur, Nand
Xu, Guozhang
Kim, Alexander J.
Baumann, Christian A.
Tuman, Robert W.
Johnson, Dana L.
Gaul, Micheal D.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[48] Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer
Wu, Zhengyang
Bai, Ying
Jin, Jiaming
Jiang, Teng
Shen, Hui
Ju, Qiurong
Zhu, Qihua
Xu, Yungen
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 217
[49] Assessment of genotype-correlated sensitivity to the investigational PI3Kα selective inhibitor MLN1117 in preclinical models.
Iartchouk, Natasha
Koenig, Erik
Shah, Pooja
Szwaya, Jeff
Fitzgerald, Michael
Zhang, Dong Mei
Cao, Yueying
Song, Keli
Brake, Rachael
[J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[50] Discovery of YS-363 as a highly potent, selective, and orally efficacious EGFR inhibitor
He, Pengxing
Jing, Jing
Du, Linna
Zhang, Xuyang
Ren, Yufei
Yang, Han
Yu, Bin
Liu, Hongmin
[J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 167

← 1 2 3 4 5 →